<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-139757" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Golimumab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhatt</surname>
            <given-names>Rajat</given-names>
          </name>
          <aff>Mahatma Gandhi Mission&#x02019;s Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rajat Bhatt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-139757.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Golimumab, a human monoclonal antibody,&#x000a0;belongs to the&#x000a0;tumor necrosis factor alpha (TNF-&#x003b1;) blockers class. This medication binds to soluble and transmembrane forms of human TNF-&#x003b1;, preventing&#x000a0;binding with receptors. The FDA has approved golimumab for treating conditions&#x000a0;such as moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PA), ankylosing spondylitis (AS), ulcerative colitis (UC), and polyarticular juvenile idiopathic arthritis (pcJIA). This&#x000a0;activity&#x000a0;discusses key aspects of golimumab usage, including&#x000a0;its mechanism of action, adverse event profile, and optimal management strategies for patients with these inflammatory conditions, particularly those unresponsive to first-line therapies.</p>
        <p>Healthcare professionals benefit from updated knowledge&#x000a0;regarding&#x000a0;golimumab administration, making informed decisions, and optimizing dosage regimens to reduce adverse reactions. This program improves patient outcomes by providing healthcare professionals with evidence-based guidance on treating RA, PA, UC, and pcJIA with golimumab. This&#x000a0;activity&#x000a0;provides healthcare professionals&#x000a0;with information regarding the latest therapeutic advances,&#x000a0;allowing for&#x000a0;better management of these challenging conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of golimumab.</p></list-item><list-item><p>Evaluate the potential adverse effects of golimumab.</p></list-item><list-item><p>Determine&#x000a0;the appropriate monitoring parameters for patients receiving golimumab.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members and patients to improve care coordination, optimize golimumab&#x000a0;therapy&#x000a0;for treating inflammatory conditions, and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=139757&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=139757">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-139757.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Golimumab is a human monoclonal antibody indicated for the&#x000a0;treatment of&#x000a0;active moderate to severe rheumatoid arthritis (RA) in sequence with&#x000a0;methotrexate (MTX), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and&#x000a0;moderate to severe ulcerative colitis (UC) in adults who did not respond to previous therapy or require ongoing steroid treatment.<xref ref-type="bibr" rid="article-139757.r1">[1]</xref><xref ref-type="bibr" rid="article-139757.r2">[2]</xref>&#x000a0;</p>
        <p>Golimumab can be used as monotherapy or concomitantly with MTX to treat PsA. This drug received FDA&#x000a0;approval in 2020&#x000a0;to treat&#x000a0;patients aged 2&#x000a0;or older with active polyarticular juvenile idiopathic arthritis (pcJIA) and PsA.<xref ref-type="bibr" rid="article-139757.r3">[3]</xref>&#x000a0;The American College of Gastroenterology guidelines&#x000a0;recommend using&#x000a0;TNF-&#x003b1; blockers like golimumab&#x000a0;to induce remission in moderate to severe active ulcerative colitis.<xref ref-type="bibr" rid="article-139757.r4">[4]</xref></p>
        <p>
<bold>FDA-Approved <bold>Indications</bold></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Rheumatoid arthritis (active moderate to severe disease)&#x000a0;in&#x000a0;adults, in combination with methotrexate&#x000a0;<xref ref-type="bibr" rid="article-139757.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Psoriatic arthritis (active disease)&#x000a0;in&#x000a0;adults</p>
          </list-item>
          <list-item>
            <p>Ankylosing spondylitis (active disease) in&#x000a0;adults&#x000a0;<xref ref-type="bibr" rid="article-139757.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Ulcerative colitis (moderate to severe disease)&#x000a0;in&#x000a0;adults&#x000a0;<xref ref-type="bibr" rid="article-139757.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Polyarticular juvenile idiopathic arthritis and psoriatic arthritis in&#x000a0;children aged 2&#x000a0;or older&#x000a0;<xref ref-type="bibr" rid="article-139757.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The American College of Rheumatology&#x000a0;recommends using&#x000a0;(TNF-&#x003b1;) blockers&#x000a0;to treat&#x000a0;non-radiographic axial spondyloarthritis.<xref ref-type="bibr" rid="article-139757.r8">[8]</xref><xref ref-type="bibr" rid="article-139757.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-139757.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Golimumab is a human monoclonal antibody that binds&#x000a0;soluble and transmembrane human TNF-&#x003b1; structures, preventing&#x000a0;their binding with TNF-&#x003b1; receptors. Tumor necrosis factor alpha is&#x000a0;a pro-inflammatory cytokine protein&#x000a0;involved in inflammation, autoimmunity, and malignancy.<xref ref-type="bibr" rid="article-139757.r10">[10]</xref>&#x000a0;Elevated levels of TNF-&#x003b1; in the joints and synovium are associated with chronic inflammatory conditions such as RA, PsA, and AS.<xref ref-type="bibr" rid="article-139757.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Following subcutaneous administration, the median time&#x000a0;for golimumab to reach maximum serum concentrations (Tmax) ranges from 2 to 6 days. The&#x000a0;estimated bioavailability of subcutaneous golimumab&#x000a0;is&#x000a0;53%. Patients&#x000a0;who produce anti-golimumab antibodies typically have lower steady-state serum trough concentrations. A drug-tolerant EIA (DT-EIA) demonstrates&#x000a0;high&#x000a0;sensitivity for detecting antidrug antibodies.<xref ref-type="bibr" rid="article-139757.r12">[12]</xref></p>
        <p><bold>Distribution:</bold> The mean volume of distribution ranges from 58 to 126 mL/kg, indicating that golimumab is primarily distributed in the circulatory system with limited extravascular distribution.</p>
        <p><bold>Metabolism:</bold> The exact metabolic pathway of golimumab remains unknown.</p>
        <p><bold>Elimination:</bold> After intravenous administration of 0.1 to 10.0 mg/kg in patients with active rheumatoid arthritis, the estimated systemic clearance of golimumab is between 4.9 and 6.7 mL/kg/day. The median terminal half-life value&#x000a0;is approximately&#x000a0;2 weeks.</p>
      </sec>
      <sec id="article-139757.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Golimumab is available&#x000a0;in&#x000a0;50 and 100 mg prefilled syringes for&#x000a0;subcutaneous injection and a&#x000a0;single-dose 50 mg/4 mL (12.5 mg/mL)&#x000a0;vial for intravenous infusion.&#x000a0;The entire vial of golimumab should be diluted with 0.9% sodium chloride to&#x000a0;a&#x000a0;total&#x000a0;volume of 100 mL.&#x000a0;This golimumab solution can be mixed in&#x000a0;a 100 mL infusion bag. Any solution remaining in vials should be discarded.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>
<bold>Rheumatoid Arthritis, Psoriatic Arthritis, and Active Ankylosing Spondylitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Golimumab is administered as a&#x000a0;2 mg/kg (IV) infusion over 30 minutes at weeks 0, 4, and 8. Afterward, this dose is repeated every 8 weeks. &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Alternatively, 50 mg (subcutaneous) every&#x000a0;4 weeks.</p>
          </list-item>
        </list>
        <p>
<bold>Ulcerative Colitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The initial dose of golimumab is 200 mg (subcutaneous).</p>
          </list-item>
          <list-item>
            <p>At week 2, 100&#x000a0;mg (subcutaneous), followed by&#x000a0;100 mg every&#x000a0;4 weeks</p>
          </list-item>
        </list>
        <p>
<bold>Pediatric Dosing</bold>
</p>
        <p>
<bold>Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Intravenous infusion (80 mg/m<sup>2</sup>)&#x000a0;over 30 minutes at weeks 0, 4, and 8. Afterward, this dose is repeated every 8 weeks.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>The product label does not include specific dosage adjustments for&#x000a0;patients with hepatic impairment.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>The product label does not include specific dosage adjustments for&#x000a0;patients with&#x000a0;renal impairment. Recent observational studies suggest that golimumab may be considered for older patients with rheumatoid arthritis and renal impairment.<xref ref-type="bibr" rid="article-139757.r13">[13]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Golimumab use&#x000a0;during pregnancy may increase the risk of infections&#x000a0;in newborns for up to 6 months after birth. Infants exposed to golimumab in utero&#x000a0;should not receive any immunization with live vaccines for 6 months following the mother's last golimumab&#x000a0;dose.&#x000a0;The American College of Rheumatology (ACR)&#x000a0;discusses the impact of placental transfer and fetal exposure for most biologic therapies, which varies with gestational stage. Biologics containing an IgG1 Fc&#x000a0;region typically do not enter the fetal circulation until the second trimester.&#x000a0;During the third trimester, administration of TNF inhibitors with these structural components (eg, infliximab, etanercept, adalimumab, and golimumab) results in placental transfer and notable neonatal drug levels. Limited evidence suggests no adverse effects, especially in the first trimester. The ACR guidelines recommend discontinuing these medications&#x000a0;for the third trimester if the disease is well-controlled. However, if the disease is active, continuing TNF inhibitors&#x000a0;to delivery is advised, though the guidelines&#x000a0;acknowledge the likelihood of significant fetal drug exposure.<xref ref-type="bibr" rid="article-139757.r14">[14]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Current data suggest that golimumab is present in breast milk at minimal levels.&#x000a0;This drug is likely to undergo partial breakdown in the infant's gastrointestinal tract, resulting in minimal absorption.&#x000a0;Given the&#x000a0;limited data, caution is advised when&#x000a0;administering&#x000a0;golimumab to a woman who is breastfeeding, particularly&#x000a0;if the infant is&#x000a0;newborn or preterm. The British Society for Rheumatology guidelines suggest that golimumab may be compatible with breastfeeding.<xref ref-type="bibr" rid="article-139757.r15">[15]</xref>&#x000a0;Holding golimumab for at least 2 weeks postpartum may significantly reduce the amount of medication transferred to the nursing infant.<xref ref-type="bibr" rid="article-139757.r16">[16]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Golimumab is indicated for active psoriatic arthritis and polyarticular juvenile idiopathic arthritis in patients aged 2 or&#x000a0;older.</p>
        <p><bold>Older patients: </bold>A&#x000a0;retrospective observational study&#x000a0;of older adults with rheumatoid arthritis and renal dysfunction assessed the persistence and safety of golimumab. The study results&#x000a0;reported consistent persistence rates across various estimated glomerular filtration rate (eGFR) groups. This persistence suggests renal function&#x000a0;does not affect golimumab&#x000a0;efficacy&#x000a0;or adverse event occurrence, underscoring its potential suitability in this population.<xref ref-type="bibr" rid="article-139757.r13">[13]</xref></p>
      </sec>
      <sec id="article-139757.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects, including severe infections and invasive fungal infections, may occur. Treatment should not be initiated during any active infections. Patients with hepatitis B are at risk for reactivation. Administration of golimumab may lead to&#x000a0;congestive heart failure (CHF) or exacerbate underlying CHF symptoms. Lupus-like syndrome and hypersensitivity reactions such as anaphylaxis may also occur. Worsening or new-onset demyelinating disorders have also been reported.<xref ref-type="bibr" rid="article-139757.r17">[17]</xref></p>
        <p>Common adverse effects associated with golimumab administration include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Upper respiratory tract infection (URTI): nasopharyngitis, pharyngitis, laryngitis, and rhinitis (13% to 16%)</p>
          </list-item>
          <list-item>
            <p>Sinusitis (2%)</p>
          </list-item>
          <list-item>
            <p>Bronchitis (2%)</p>
          </list-item>
          <list-item>
            <p>Viral infections (4% to 5%)</p>
          </list-item>
          <list-item>
            <p>Bronchitis (2% to 3%)</p>
          </list-item>
          <list-item>
            <p>Injection site reaction: pain, redness, urticaria, induration, bruising, pruritus, irritation (3% to 6%)</p>
          </list-item>
          <list-item>
            <p>Elevated liver enzymes: alanine aminotransferase (4%), aspartate aminotransferase (3%)</p>
          </list-item>
          <list-item>
            <p>Hypertension (3%)</p>
          </list-item>
          <list-item>
            <p>Dizziness (2%)</p>
          </list-item>
          <list-item>
            <p>Paresthesia (2%)</p>
          </list-item>
          <list-item>
            <p>Constipation (1%)</p>
          </list-item>
          <list-item>
            <p>Pyrexia (2%)</p>
          </list-item>
          <list-item>
            <p>Leukopenia (1%)</p>
          </list-item>
          <list-item>
            <p>Superficial fungal infections (2%)</p>
          </list-item>
          <list-item>
            <p>Posterior reversible encephalopathy syndrome&#x000a0;<xref ref-type="bibr" rid="article-139757.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Peripheral neuropathy&#x000a0;<xref ref-type="bibr" rid="article-139757.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Golimumab should not be administered concomitantly&#x000a0;with biologic disease-modifying antirheumatic drugs (DMARDs)&#x000a0;or Janus kinase&#x000a0;inhibitors (JAKi). Examples of biologic DMARDs include TNF-&#x003b1; inhibitors (eg, infliximab), interleukin inhibitors (eg, ustekinumab), B-cell inhibitors (eg, rituximab), T-cell inhibitors (eg, Abatacept). Biologic Janus kinase inhibitors include tofacitinib, baricitinib, upadacitinib, and filgotinib.</p>
          </list-item>
          <list-item>
            <p>The administration of live vaccines&#x000a0;to patients undergoing&#x000a0;golimumab therapy is not recommended.</p>
          </list-item>
          <list-item>
            <p>The&#x000a0;concomitant&#x000a0;administration of&#x000a0;antibiotics&#x000a0;or antiviral therapy and&#x000a0;golimumab is not recommended.<xref ref-type="bibr" rid="article-139757.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic inflammation increases TNF-&#x003b1; levels, suppressing cytochrome P450 (CYP450) enzymes. Golimumab administration may normalize the activity of these enzymes. Patients receiving golimumab and medications&#x000a0;with a narrow therapeutic index&#x000a0;that are metabolized by CYP450 enzymes (eg, warfarin, cyclosporine, and theophylline) should be monitored closely.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-139757.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>No labeled contraindications have been reported.</p>
        <p>
<bold>Box Warnings</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Severe infections</bold>: Using golimumab can result in serious infections, which may cause hospitalization or even death. Diseases such as bacterial sepsis, tuberculosis (TB), and fungal and opportunistic infections have been reported. Reported infections include coccidioidomycosis, candidiasis, listeriosis, aspergillosis, blastomycosis, and histoplasmosis.<xref ref-type="bibr" rid="article-139757.r20">[20]</xref>&#x000a0;Treatment with golimumab should be discontinued if any of these infections ensue.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Malignancies</bold>: Lymphoma and additional malignancies, some fatal, have also been reported with the use of TNF inhibitors in pediatric populations.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Tuberculosis:</bold> A TB test should be performed before initiating golimumab. For latent infection, treatment should be initiated before starting golimumab. Patients receiving golimumab should be monitored for the development of active TB regardless of a negative initial test.<xref ref-type="bibr" rid="article-139757.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hepatitis B virus reactivation:</bold> Patients with HBV receiving treatment with golimumab should be monitored&#x000a0;for HBV reactivation after initiating therapy. In the event of a reactivation, golimumab should be stopped immediately, and antiviral treatment should be initiated.<xref ref-type="bibr" rid="article-139757.r11">[11]</xref><xref ref-type="bibr" rid="article-139757.r17">[17]</xref>&#x000a0;Antiviral therapy should be continued for at least&#x000a0;6 months after discontinuing golimumab due to potential HBV reactivation.<xref ref-type="bibr" rid="article-139757.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Demyelinating disorders:</bold> Cases of new or exacerbated CNS demyelinating disorders like multiple sclerosis and peripheral demyelinating disorders like Guillain-Barre syndrome have been reported in patients&#x000a0;receiving golimumab therapy. This drug should be used with caution in patients with pre-existing demyelinating disorders and&#x000a0;should be discontinued if these conditions develop.<xref ref-type="bibr" rid="article-139757.r23">[23]</xref><xref ref-type="bibr" rid="article-139757.r24">[24]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Autoimmunity:</bold> Golimumab treatment may lead to antinuclear antibody formation and, rarely, a lupus-like syndrome. Golimumab should be discontinued if TNF-&#x003b1; antagonist-induced lupus-like syndrome (TAILS) occurs.<xref ref-type="bibr" rid="article-139757.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Combination therapy:</bold> Golimumab with abatacept (another biologic) or anakinra (an interleukin-1 antagonist) is not recommended due to the increased risk of infections and lack of additional benefit.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hematologic cytopenias:</bold>&#x000a0;Pancytopenia, leukopenia, neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia have been reported in patients receiving golimumab therapy. This drug should be used with caution in patients with a history of significant cytopenias.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Congestive Heart Failure (CHF):</bold>&#x000a0;Golimumab use is associated with worsening or new-onset CHF, including fatalities. This drug should be used with caution in patients with existing CHF. These patients should be closely monitored for worsening symptoms. Discontinuing golimumab may be necessary.<xref ref-type="bibr" rid="article-139757.r26">[26]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-139757.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Testing for active or latent tuberculosis (TB) (ie, tuberculin skin test (TST) or interferon-&#x003b3; release assay (IGRA)) should occur before initiating golimumab therapy. Patients should also be routinely monitored&#x000a0;during&#x000a0;TB treatment after starting&#x000a0;golimumab therapy.&#x000a0;Patients with latent TB should be treated before initiating golimumab. Patients should also receive a baseline complete blood count (CBC) and routinely afterward. Patients with an active infection should not be started on golimumab. Monitoring for bacterial, viral, fungal, or opportunistic infections while on treatment is also advised. The Ankylosing Spondylitis Disease Activity Score (ASDAS) is useful for monitoring response to therapy.<xref ref-type="bibr" rid="article-139757.r27">[27]</xref></p>
        <p>Elevated alanine aminotransferase and aspartate aminotransferase levels&#x000a0;have been documented. Patients with underlying CHF receiving golimumab should have regular check-ups for worsening CHF.&#x000a0;Subjects with underlying HBV receiving therapy with golimumab should be assessed regularly for HBV reactivation. In the event of viral reactivation, golimumab should be stopped,&#x000a0;and appropriate treatment should be initiated.<xref ref-type="bibr" rid="article-139757.r28">[28]</xref></p>
      </sec>
      <sec id="article-139757.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Doses up to 10 mg/kg of intravenous golimumab have been administered in a clinical study without reports of severe adverse reactions.&#x000a0;</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There is no antidote for golimumab. A poison control center or medical toxicologist should be consulted for more information.<xref ref-type="bibr" rid="article-139757.r29">[29]</xref></p>
      </sec>
      <sec id="article-139757.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Golimumab is a tumor necrosis factor-alpha (TNF-&#x003b1;) inhibitor targeting the human TNF-&#x003b1;&#x000a0;cytokine protein&#x000a0;and further preventing binding with its receptors. This drug is FDA-approved for&#x000a0;treating active moderate to severe rheumatoid arthritis in sequence with first-line therapy methotrexate, active psoriatic arthritis, active ankylosing spondylitis, and patients with moderate to severe ulcerative colitis unable to achieve an adequate response to previous therapy, or patients requiring ongoing treatment with steroid. Golimumab recently&#x000a0;received FDA approval in 2020 for its indication in the pediatric population on treating active polyarticular juvenile idiopathic arthritis and psoriatic arthritis&#x000a0;in patients&#x000a0;aged&#x000a0;2&#x000a0;and older.</p>
        <p>Treating&#x000a0;patients with inflammatory and autoimmune&#x000a0;conditions requires coordination from&#x000a0;an interprofessional&#x000a0;healthcare team. Immediate clinical examination and diagnosis can enhance the efficiency of treatment plans, mitigating debilitating symptoms and increasing the quality of the patient's life. The interprofessional treatment team comprises a primary care physician (PCP), a rheumatologist, a gastroenterologist, nurse practitioners, physician assistants, nurses, a physical therapist (PT), and a pharmacist.&#x000a0;Pharmacists should verify dosing, perform drug interaction checks, and report discrepancies to the prescriber. Nurses should monitor patients for adherence and clinical response.</p>
        <p>Continuous interaction between the prescribing specialist and PCP should be maintained with their patient's care. The treatment team should also be regularly updated with the latest guidelines on their patient's disease management. The interprofessional team should thoroughly educate and counsel patients&#x000a0;on golimumab. Patients should be aware of any potential adverse effects that may occur and be advised to report any new onset unsuspected symptoms. Golimumab administration should be&#x000a0;performed in a healthcare setting where the interprofessional care team is&#x000a0;prepared for immediate adverse effects such as hypersensitivity reactions (hives, pruritus, dyspnea, nausea, angioedema, urticaria, anaphylaxis). In any severe events such as anaphylaxis, the treatment should be immediately stopped, and appropriate management should be initiated.</p>
        <p>While treating patients with golimumab, the healthcare team should monitor the patients' complete blood count, liver enzymes, and TB test before initiating the treatment and routinely afterward. TB screening with a tuberculin skin test (TST) or interferon-&#x003b3; release assay (IGRA) should be performed on all patients. Patients who present a positive TB test should receive management for TB before initiating treatment with golimumab. Patients with a history of HBV receiving golimumab should routinely be monitored for HBV reactivation and discontinue therapy if reactivation does ensue. The team should discuss the treatment's potential benefits and risks with all patients planning to start golimumab therapy.</p>
        <p>Patients should be informed about the box warnings indicating an increased risk of potentially severe infections and malignancy. Patients should immediately report any new onset constitution symptoms indicative of severe infections to their PCP to prevent complications, hospitalization, and potential mortality. An interprofessional team approach and communication among clinicians (MDs, DOs, NPs, PAs), rheumatologists, pharmacists, and nurses is crucial to increasing medication compliance further, decreasing potential adverse effects, and improving disease course and quality of life.<xref ref-type="bibr" rid="article-139757.r30">[30]</xref></p>
      </sec>
      <sec id="article-139757.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=139757&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=139757">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/139757/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=139757">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-139757.s11">
        <title>References</title>
        <ref id="article-139757.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayashi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[Golimumab].</article-title>
            <source>Nihon Rinsho</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>1227</fpage>
            <page-range>1227-31</page-range>
            <pub-id pub-id-type="pmid">23961671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Samaan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Irving</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Golimumab in the treatment of ulcerative colitis.</article-title>
            <source>Therap Adv Gastroenterol</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>1756284818821266</fpage>
            <pub-id pub-id-type="pmid">30728858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seidel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Skrabl-Baumgartner</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab.</article-title>
            <source>Pediatr Rheumatol Online J</source>
            <year>2021</year>
            <month>Aug</month>
            <day>21</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>132</fpage>
            <pub-id pub-id-type="pmid">34419092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubin</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Ananthakrishnan</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Sauer</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>ACG Clinical Guideline: Ulcerative Colitis in Adults.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>114</volume>
            <issue>3</issue>
            <fpage>384</fpage>
            <page-range>384-413</page-range>
            <pub-id pub-id-type="pmid">30840605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsuchiya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Masuda</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Golimumab in Rheumatoid Arthritis Patients at High Risk of a Poor Prognosis: Post-Hoc Analysis of GO-FORTH Study using Cluster Analysis.</article-title>
            <source>Mod Rheumatol</source>
            <year>2024</year>
            <month>May</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">38780239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Viapiana</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Orsolini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fracassi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Idolazzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gatti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Govoni</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?</article-title>
            <source>Reumatismo</source>
            <year>2015</year>
            <month>Mar</month>
            <day>31</day>
            <volume>66</volume>
            <issue>4</issue>
            <fpage>285</fpage>
            <page-range>285-303</page-range>
            <pub-id pub-id-type="pmid">25829189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campas-Moya</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-22</page-range>
            <pub-id pub-id-type="pmid">20200692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinstein</surname>
                <given-names>CLJ</given-names>
              </name>
              <name>
                <surname>Sliwinska-Stanczyk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>H&#x000e1;la</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stanislav</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tzontcheva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berd</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK).</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2023</year>
            <month>Nov</month>
            <day>02</day>
            <volume>62</volume>
            <issue>11</issue>
            <fpage>3601</fpage>
            <page-range>3601-3609</page-range>
            <pub-id pub-id-type="pmid">36919768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deodhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gensler</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Dubreuil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Haroon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Borenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biehl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Louie</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Majithia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bigham</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pianin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oristaglio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maksymowych</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>71</volume>
            <issue>10</issue>
            <fpage>1285</fpage>
            <page-range>1285-1299</page-range>
            <pub-id pub-id-type="pmid">31436026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Padda</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Parmar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Biosimilars Use in Medicine for Inflammatory Diseases</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">34662086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gerriets</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khaddour</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Tumor Necrosis Factor Inhibitors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">29494032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Adedokun</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Gargano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hsia</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shankar</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>441</fpage>
            <page-range>441-446</page-range>
            <pub-id pub-id-type="pmid">30412238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yokoyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Masuda</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Persistence and Safety of Golimumab in Elderly Patients with Rheumatoid Arthritis and Renal Dysfunction in a Real-World Setting.</article-title>
            <source>Drugs Real World Outcomes</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-60</page-range>
            <pub-id pub-id-type="pmid">36334249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sammaritano</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Bermas</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Chakravarty</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clowse</surname>
                <given-names>MEB</given-names>
              </name>
              <name>
                <surname>Lockshin</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Marder</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Branch</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Buyon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Christopher-Stine</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Crow-Hercher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cush</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Druzin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laskin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Plante</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salmon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Simard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Somers</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Steen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tedeschi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Vinet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Yazdany</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barbhaiya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bettendorf</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Eudy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jayatilleke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tarter</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Birru Talabi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Anci</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>529</fpage>
            <page-range>529-556</page-range>
            <pub-id pub-id-type="pmid">32090480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russell</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Dey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flint</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crossley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frishman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gayed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hodson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Khamashta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Panchal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Piper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Saxby</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Senvar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tosounidou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van de Venne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Warburton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>I</given-names>
              </name>
              <collab>BSR Standards, Audit and Guidelines Working Group</collab>
            </person-group>
            <article-title>British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2023</year>
            <month>Apr</month>
            <day>03</day>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>e48</fpage>
            <page-range>e48-e88</page-range>
            <pub-id pub-id-type="pmid">36318966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Golimumab</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Godfrey</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>LN</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor-&#x003b1; and Beyond.</article-title>
            <source>Clin Chest Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>721</fpage>
            <page-range>721-739</page-range>
            <pub-id pub-id-type="pmid">31731980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000c7;imen G&#x000fc;ne&#x0015f;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>&#x000c7;olak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tekg&#x000f6;z</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>&#x000c7;&#x00131;nar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Y&#x00131;lmaz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Golimumab-induced posterior reversible encephalopathy syndrome (PRES): a case-based review.</article-title>
            <source>Clin Rheumatol</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>12</issue>
            <fpage>3407</fpage>
            <page-range>3407-3410</page-range>
            <pub-id pub-id-type="pmid">37715081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Neurological disorders following the use of tumor necrosis factor-&#x003b1; inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2024</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>8</issue>
            <fpage>1041</fpage>
            <page-range>1041-1048</page-range>
            <pub-id pub-id-type="pmid">38769926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors.</article-title>
            <source>Exp Biol Med (Maywood)</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>245</volume>
            <issue>13</issue>
            <fpage>1104</fpage>
            <page-range>1104-1114</page-range>
            <pub-id pub-id-type="pmid">32640893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>So</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Drug Persistence and Incidence of Active Tuberculosis of Tumor Necrosis Factor Alpha Inhibitors Versus Tocilizumab as the First-Line Biological Treatment in Patients with Rheumatoid Arthritis: A Nationwide Population-Based Retrospective Cohort Analysis.</article-title>
            <source>Rheumatol Ther</source>
            <year>2024</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>881</fpage>
            <page-range>881-895</page-range>
            <pub-id pub-id-type="pmid">38769252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Golimumab</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>2</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31643442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nyboe Andersen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>G&#x000f8;rtz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thorn Iversen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000f8;jgaard Allin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beaugerie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kirchgesner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jess</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>135</fpage>
            <page-range>135-143.e8</page-range>
            <pub-id pub-id-type="pmid">37442315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kudsi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shahada</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Haidar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Safiah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Khalayli</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Golimumab therapy-induced isolated myelitis in a Behcet's disease patient: a case report.</article-title>
            <source>Ann Med Surg (Lond)</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>85</volume>
            <issue>4</issue>
            <fpage>951</fpage>
            <page-range>951-954</page-range>
            <pub-id pub-id-type="pmid">37113905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brunasso</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Aberer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Massone</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritis.</article-title>
            <source>Lupus</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>201</fpage>
            <page-range>201-3</page-range>
            <pub-id pub-id-type="pmid">24356614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziyadeh</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Geldhof</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>No&#x000eb;l</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Otero-Lobato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esslinger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chakravarty</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database.</article-title>
            <source>Clin Drug Investig</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>1021</fpage>
            <page-range>1021-1040</page-range>
            <pub-id pub-id-type="pmid">32779120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michielsens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bolhuis</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>van Gaalen</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>van den Hoogen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Verhoef</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>den Broeder</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>den Broeder</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study.</article-title>
            <source>Scand J Rheumatol</source>
            <year>2024</year>
            <month>May</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>180</fpage>
            <page-range>180-187</page-range>
            <pub-id pub-id-type="pmid">37339375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lasa</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Olivera</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Danese</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peyrin-Biroulet</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.</article-title>
            <source>Lancet Gastroenterol Hepatol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-170</page-range>
            <pub-id pub-id-type="pmid">34856198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobitz</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Nailon</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>The Role of a Regional Poison Center in Assessing and Managing Disaster Risk.</article-title>
            <source>Health Secur</source>
            <year>2020</year>
            <season>May/Jun</season>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-204</page-range>
            <pub-id pub-id-type="pmid">32559158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-139757.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melo</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Campanilho-Marques</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Golimumab (anti-TNF monoclonal antibody): where we stand today.</article-title>
            <source>Hum Vaccin Immunother</source>
            <year>2021</year>
            <month>Jun</month>
            <day>03</day>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1586</fpage>
            <page-range>1586-1598</page-range>
            <pub-id pub-id-type="pmid">33369527</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
